Physician profile
Wenxin Wei
NPI 1861605586
$1,520.43
in general payments reported to CMS, 2019-2025
16 companies · $523 in 2025
The $523 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $96.60 · 2021: $191 · 2022: $115 · 2023: $252 · 2024: $147 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $921.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $236.28 | 2019-2025 | Argos, Clareon Panoptix Pro, Hydrus Microstent |
| Bausch & Lomb Americas INC. | $217.56 | 2023-2025 | Vyzulta, Xiidra, Miebo |
| Allergan, INC. | $194.46 | 2019-2021 | |
| Dompe US, INC. | $183.94 | 2025 | Oxervate |
| Horizon Therapeutics Plc | $137.84 | 2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $130.53 | 2019-2025 | Cequa |
| Biotissue Holdings INC. | $101.68 | 2019-2025 | |
| Abbvie INC. | $87.19 | 2023-2025 | Lumigan, Alphagan P |
| Novartis Pharmaceuticals Corporation | $47.90 | 2019-2020 | |
| Amgen INC. | $38.86 | 2024-2025 | Tepezza |
| Ocular Therapeutix, INC. | $32.11 | 2021-2023 | Dextenza |
| Omeros Corporation | $32.00 | 2021 | |
| Oyster Point Pharma, INC. | $28.35 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Aerie Pharmaceuticals, INC. | $17.17 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $15.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wenxin Wei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.